<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677972</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-1005-351</org_study_id>
    <nct_id>NCT04677972</nct_id>
  </id_info>
  <brief_title>SPI-1005 for the Treatment of Meniere's Disease</brief_title>
  <acronym>STOPMD-3</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sound Pharmaceuticals, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sound Pharmaceuticals, Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial&#xD;
      (RCT) with open-label extension study (OLE), of SPI-1005 in adult subjects with definite&#xD;
      Meniere's disease with active symptoms within three months preceding study enrollment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>84 days</time_frame>
    <description>Safety and tolerability assessed based on comparison of adverse events vs. placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in low frequency hearing thresholds measured by pure tone audiometry</measure>
    <time_frame>56 days</time_frame>
    <description>Co-primary efficacy endpoint; assessment of hearing by pure tone audiometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Words-in-Noise Test score</measure>
    <time_frame>56 days</time_frame>
    <description>Co-primary efficacy endpoint; assessment of word recognition by Words-in-Noise Test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tinnitus severity</measure>
    <time_frame>56 days</time_frame>
    <description>Tinnitus Functional Index (0-100) where higher score is worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tinnitus loudness</measure>
    <time_frame>56 days</time_frame>
    <description>Tinnitus Functional Index Question #2 -- How Strong or Loud was your Tinnitus? (0-10) where higher score is worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vertigo severity</measure>
    <time_frame>56 days</time_frame>
    <description>Vertigo Symptom Scale (0-60) where higher score is worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aural fullness</measure>
    <time_frame>56 days</time_frame>
    <description>Aural Fullness Scale (0-10) where higher score is worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dizziness</measure>
    <time_frame>56 days</time_frame>
    <description>Dizziness Handicap Inventory (0-100) where higher score is worse outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Meniere Disease</condition>
  <condition>Ménière</condition>
  <arm_group>
    <arm_group_label>SPI-1005 400 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of SPI-1005 400 mg BID for 28 days, with 84-day followup</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of matching placebo BID for 28 days, with 84-day followup</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ebselen</intervention_name>
    <description>Glutathione peroxidase mimetic</description>
    <arm_group_label>SPI-1005 400 mg BID</arm_group_label>
    <other_name>SPI-1005</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo containing excipients</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult males/females, 18-75 years of age at the time of enrollment.&#xD;
&#xD;
          -  Diagnosis of definite Meniere's Disease by AAO-HNS Amended 2015 Criteria.&#xD;
&#xD;
          -  Hearing loss of ≥30 dB at 250, 500, or 1000 Hz at study enrollment.&#xD;
&#xD;
          -  At least two of three active symptoms (tinnitus; aural fullness; vertigo or dizziness)&#xD;
             of Meniere's disease by AAO-HNS Amended 2015 Criteria, within 3 months of study&#xD;
             enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current, or within 60 days prior to study enrollment, use of IV ototoxic medications&#xD;
&#xD;
          -  History of otosclerosis or vestibular schwannoma.&#xD;
&#xD;
          -  History of significant middle ear or inner ear surgery in the affected ear.&#xD;
&#xD;
          -  Conductive hearing loss with air-bone gap ≥15 dB, otitis media, or mixed hearing loss.&#xD;
&#xD;
          -  Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal,&#xD;
             endocrine, immunologic, neurological, or psychiatric disease.&#xD;
&#xD;
          -  Current use or within 30 days prior to study enrollment systemic steroids.&#xD;
&#xD;
          -  Current use or within 7 days prior to study enrollment intratympanic steroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan Kil, MD</last_name>
    <phone>2066342559</phone>
    <email>info@soundpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>House Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced ENT &amp; Allergy</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Ear Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19144</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kil J, Harruff EE, Longenecker RJ. Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hear Res. 2021 Feb 19:108209. doi: 10.1016/j.heares.2021.108209. [Epub ahead of print]</citation>
    <PMID>33678494</PMID>
  </reference>
  <reference>
    <citation>Kil J, Pierce C, Tran H, Gu R, Lynch ED. Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hear Res. 2007 Apr;226(1-2):44-51. Epub 2006 Oct 6.</citation>
    <PMID>17030476</PMID>
  </reference>
  <reference>
    <citation>Kil J, Lobarinas E, Spankovich C, Griffiths SK, Antonelli PJ, Lynch ED, Le Prell CG. Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017 Sep 2;390(10098):969-979. doi: 10.1016/S0140-6736(17)31791-9. Epub 2017 Jul 14.</citation>
    <PMID>28716314</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ebselen</keyword>
  <keyword>hearing loss</keyword>
  <keyword>tinnitus</keyword>
  <keyword>vertigo</keyword>
  <keyword>dizziness</keyword>
  <keyword>SPI-1005</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meniere Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ebselen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

